“…It has been postulated that potentiation by bretylium is related to monoamine oxidase inhibition (Goldberg & Sjoerdsma, 1959), which bretylium has been shown to produce (Kuntzman & Jacobson, 1963;Dvornic et al, 1963;Furehgott, 1964;Furchgott & Sanchez-Garcia, 1966;Giachetti & Shore, 1967;Carlsson & Waldeck, 1967). Thus, in reserpinized animals, potentiation of the cardiovascular response to tyramine produced by bretylium might be explained on the basis of this enzyme inhibitory action (Furchgott, 1964;Furchgott & Sanchez-Garcia, 1966;Clarke & Leach, 1968). Goldberg (1964), Sjoqvist (1965, and other workers who have reported interactions between monoamine oxidase inhibitors and sympathomimetic amines, base their explanation on the following sequence of events: when intraneuronal monoamine oxidase is inhibited, the noradrenaline stores increase and hence larger amounts of noradrenaline are liberated by noradrenaline-releasing drugs.…”